Ery-tab
NDC Package 21695-457-15

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Ery-tab is erythromycin is used to treat a wide variety of bacterial infections. Marketed by Rebel Distributors Corp, this product is identified by NDC 21695-457 and is authorized under FDA application ANDA061621.

Identification & Billing

NDC Package Code
21695-457-15
Package Description
15 TABLET, DELAYED RELEASE in 1 BOTTLE
Product Code
21695-457
11-Digit Billing Format
21695045715
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ery-tab
Dosage Form
-
Usage Information
Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Regulatory & Marketing

Labeler Name
Rebel Distributors Corp
FDA Application #
ANDA061621
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-11-1972
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (21695-457). Click a package code to view its specific billing and regulatory data.

21695-457-21
21 TABLET, DELAYED RELEASE in 1 BOTTLE
21695-457-30
30 TABLET, DELAYED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 21695-457-15 identifies a specific commercial package of 15 tablet, delayed release in 1 bottle of Ery-tab, labeled by Rebel Distributors Corp. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Rebel Distributors Corp on July 11, 1972. The current certification is valid through December 31, 2017.

What are the primary indications for this medication?

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

How is this Rebel Distributors Corp product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 21695045715. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
21695-457-15
11-Digit CMS (5-4-2)
21695-0457-15

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.